Interleukin-1β mediated amyloid plaque clearance is independent of CCR2 signaling in the APP/PS1 mouse model of Alzheimer's disease

Neurobiology of Disease

Volumn 69, Issue , 2014, Pages 124-133

  Rivera Escalera, Fátima ^a   Matousek, Sarah B ^a,b   Ghosh, Simantini ^a,c   Olschowka, John A ^a   O'banion, M Kerry ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Bone marrow derived; CCL2; CCR2; Interleukin 1 ; Monocytes; Neuroinflammation

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CHEMOKINE RECEPTOR CCR2; INTERLEUKIN 1BETA; PRESENILIN 1; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APP PROTEIN, HUMAN; CCR2 PROTEIN, MOUSE; IL1B PROTEIN, HUMAN; PEPTIDE FRAGMENT; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HIPPOCAMPUS; IMMUNOCOMPETENT CELL; MONOCYTE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL; GENETICS; HISTOCOMPATIBILITY; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MONONUCLEAR CELL; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MICE, TRANSGENIC; NEUROIMMUNOMODULATION; PEPTIDE FRAGMENTS; PLAQUE, AMYLOID; PRESENILIN-1; RECEPTORS, CCR2; SIGNAL TRANSDUCTION; TRANSPLANTATION CHIMERA;

EID: 84902185288     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.05.018     Document Type: Article

References (37)

1. Akiyama H., et al. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
2. Benzing W.C., et al. Evidence for glial-mediated inflammation in aged APP(SW) transgenic mice. Neurobiol. Aging 1999, 20:581-589.
3. Boissonneault V., et al. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain 2009, 132:1078-1092.
4. Burger C., et al. Recombinant adeno-associated viral vectors in the nervous system. Hum. Gene Ther. 2005, 16:781-791.
5. Butovsky O., et al. Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur. J. Neurosci. 2007, 26:413-416.
6. Chakrabarty P., et al. IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J. Immunol. 2010, 184:5333-5343.
7. Chakrabarty P., et al. Hippocampal expression of murine TNFalpha results in attenuation of amyloid deposition in vivo. Mol. Neurodegener. 2011, 6:16.
8. Chakrabarty P., et al. Massive gliosis induced by interleukin-6 suppresses Abeta deposition in vivo: evidence against inflammation as a driving force for amyloid deposition. FASEB J. 2010, 24:548-559.
9. Davidson B.L., et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3428-3432.
10. El Khoury J., et al. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat. Med. 2007, 13:432-438.
11. Ghosh S., et al. Sustained interleukin-1beta overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J. Neurosci. 2013, 13:5053-5064.
12. Gomez-Nicola D., et al. Differential role of CCR2 in the dynamics of microglia and perivascular macrophages during prion disease. Glia 2014, Mar 19. 10.1002/glia.22660.
13. Griffin W.S., et al. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J. Neuropathol. Exp. Neurol. 1995, 54:276-281.
14. Griffin W.S., et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:7611-7615.
15. Heneka M.T., et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013, 493:674-678.
16. Heneka M.T., O'banion M.K. Inflammatory processes in Alzheimer's disease. J. Neuroimmunol. 2007, 184:69-91.
17. Itagaki S., et al. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 1989, 24:173-182.
18. Kraft A.W., et al. Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB J. 2013, 27:187-198.
19. Lee C.Y., Landreth G.E. The role of microglia in amyloid clearance from the AD brain. J. Neural Transm. 2010, 117:949-960.
20. Liu Z., et al. CX3CR1 in microglia regulates brain amyloid deposition through selective protofibrillar amyloid-beta phagocytosis. J. Neurosci. 2010, 30:17091-17101.
21. Matousek S.B., et al. Chronic IL-1beta-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer's disease without inducing overt neurodegeneration. J. Neuroimmune Pharmacol. 2012, 7:156-164.
22. Mildner A., et al. Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J. Neurosci. 2011, 31:11159-11171.
23. Montgomery S.L., et al. Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-alpha suppressive therapeutic strategies in the brain. Am. J. Pathol. 2011, 179:2053-2070.
24. Montgomery S.L., et al. Chronic neuron- and age-selective down-regulation of TNF receptor expression in triple-transgenic Alzheimer disease mice leads to significant modulation of amyloid- and Tau-related pathologies. Am. J. Pathol. 2013, 182:2285-2297.
25. Moravan M.J., et al. Cranial irradiation leads to acute and persistent neuroinflammation with delayed increases in T-cell infiltration and CD11c expression in C57BL/6 mouse brain. Radiat. Res. 2011, 176:459-473.
26. Rezai-Zadeh K., et al. How to get from here to there: macrophage recruitment in Alzheimer's disease. Curr. Alzheimer Res. 2011, 8:156-163.
27. Ryan D.A., et al. Abeta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Mol. Ther. 2010, 18:1471-1481.
28. Saederup N., et al. Selective chemokine receptor usage by central nervous system myeloid cells in CCR2-red fluorescent protein knock-in mice. PLoS One 2010, 5:e13693.
29. Shaftel S.S., et al. Chronic interleukin-1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J. Neurosci. 2007, 27:9301-9309.
30. Shaftel S.S., et al. Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. J. Clin. Invest. 2007, 117:1595-1604.
31. Sheng J.G., et al. Human brain S100 beta and S100 beta mRNA expression increases with age: pathogenic implications for Alzheimer's disease. Neurobiol. Aging 1996, 17:359-363.
32. Shi C., Pamer E.G. Monocyte recruitment during infection and inflammation. Nat. Rev. Immunol. 2011, 11:762-774.
33. Simard A.R., et al. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006, 49:489-502.
34. Town T., et al. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat. Med. 2008, 14:681-687.
35. Urabe M., et al. Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 2002, 13:1935-1943.
36. Wu M.D., et al. Sustained IL-1beta expression impairs adult hippocampal neurogenesis independent of IL-1 signaling in nestin+neural precursor cells. Brain Behav. Immun. 2013, 32:9-18.
37. Wyss-Coray T., et al. TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat. Med. 2001, 7:612-618.